Regional Differences in the Burden of MDR-TB and XDR-TB in Kazakhstan Between 2013 and 2022

Background/Objectives: Tuberculosis (TB) remains one of the leading infectious causes of death worldwide, while multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB continue to pose major global health challenges. Kazakhstan is among the 30 high MDR-TB burden countries prioritized by the World Health Organization (WHO). This study aimed to assess national and regional trends in the burden of MDR-TB and XDR-TB in Kazakhstan between 2013 and 2022. Methods: We conducted a retrospective population-based study using anonymized case-level records of the National Tuberculosis Register of Kazakhstan for 2013–2022; duplicate registrations due to transfers were removed. Crude and age-standardized prevalence and mortality rates were calculated at the national and regional levels. Disability-adjusted life years (DALYs) were estimated as the sum of years of life lost (YLL) and years lived with disability (YLD), following the Global Burden of Disease methodology, using WHO-based treatment durations and HIV-specific disability weights. The burden was additionally assessed by sex and age group, and associations between regional burden and socio-economic and health-system indicators were assessed using Spearman correlation and linear mixed models. Results: Between 2013 and 2022, crude MDR-TB prevalence decreased from 40.80 to 22.35 per 100,000 population (−45.2%) and XDR-TB prevalence from 2.12 to 0.05 per 100,000 (−97.8%). TB mortality among MDR-TB patients decreased by 71.5%, and no XDR-TB deaths were recorded in 2022. The age-standardized DALY rate of drug-resistant TB decreased from 97.0 to 27.8 per 100,000 (−71.3%). DALYs were 2.3–2.6 times higher among men than among women, with the greatest burden in working-age groups. In 2022, the highest burden was observed in West Kazakhstan, Kyzylorda and North Kazakhstan. DR-TB prevalence was higher in regions with more recipients of targeted social assistance, and per capita income was not associated with the burden; higher physician density was associated with lower DALY rates in the main analysis, but not consistently in sensitivity analyses. Conclusions: Kazakhstan experienced substantial reductions in the burden of MDR-TB and XDR-TB during 2013–2022. However, persistent sex and regional differences indicate that these improvements were not uniform across the population. Continued surveillance and targeted interventions in higher-burden population groups and regions remain important for further reducing the burden of drug-resistant TB.

Authors

Institutions

Publication Details

Journal
Healthcare
Published
2026-11-16
DOI
https://doi.org/10.3390/healthcare14223923
Primary Topic
Tuberculosis Research and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Regional Differences in the Burden of MDR-TB and XDR-TB in Kazakhstan Between 2013 and 2022

Meruyert Suleimenova, Gauhar Dunenova, Zhansaya Nurgaliyeva, Ainash Oshibayeva et al.
4 links
Healthcare
Tuberculosis Research and Epidemiology
article

Regional Differences in the Burden of MDR-TB and XDR-TB in Kazakhstan Between 2013 and 2022

Meruyert Suleimenova, Gauhar Dunenova, Zhansaya Nurgaliyeva, Ainash Oshibayeva, Fatima Kassymbekova, Nailya Kozhekenova, M Idayat, Natalya Glushkova, Malik Adenov, Kairat Davletov, Elena Von Der Lippe
article en

Abstract

Background/Objectives: Tuberculosis (TB) remains one of the leading infectious causes of death worldwide, while multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB continue to pose major global health challenges. Kazakhstan is among the 30 high MDR-TB burden countries prioritized by the World Health Organization (WHO). This study aimed to assess national and regional trends in the burden of MDR-TB and XDR-TB in Kazakhstan between 2013 and 2022. Methods: We conducted a retrospective population-based study using anonymized case-level records of the National Tuberculosis Register of Kazakhstan for 2013–2022; duplicate registrations due to transfers were removed. Crude and age-standardized prevalence and mortality rates were calculated at the national and regional levels. Disability-adjusted life years (DALYs) were estimated as the sum of years of life lost (YLL) and years lived with disability (YLD), following the Global Burden of Disease methodology, using WHO-based treatment durations and HIV-specific disability weights. The burden was additionally assessed by sex and age group, and associations between regional burden and socio-economic and health-system indicators were assessed using Spearman correlation and linear mixed models. Results: Between 2013 and 2022, crude MDR-TB prevalence decreased from 40.80 to 22.35 per 100,000 population (−45.2%) and XDR-TB prevalence from 2.12 to 0.05 per 100,000 (−97.8%). TB mortality among MDR-TB patients decreased by 71.5%, and no XDR-TB deaths were recorded in 2022. The age-standardized DALY rate of drug-resistant TB decreased from 97.0 to 27.8 per 100,000 (−71.3%). DALYs were 2.3–2.6 times higher among men than among women, with the greatest burden in working-age groups. In 2022, the highest burden was observed in West Kazakhstan, Kyzylorda and North Kazakhstan. DR-TB prevalence was higher in regions with more recipients of targeted social assistance, and per capita income was not associated with the burden; higher physician density was associated with lower DALY rates in the main analysis, but not consistently in sensitivity analyses. Conclusions: Kazakhstan experienced substantial reductions in the burden of MDR-TB and XDR-TB during 2013–2022. However, persistent sex and regional differences indicate that these improvements were not uniform across the population. Continued surveillance and targeted interventions in higher-burden population groups and regions remain important for further reducing the burden of drug-resistant TB.

HealthcareVol. 14(22)
Al-Farabi Kazakh National University (KZ), Kazakh National Medical University (KZ), Robert Koch Institute (DE), Ahmet Yesevi University (KZ)
Good health and well-being
Tuberculosis Research and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon